New York based investment bank, Ladenburg Thalmann & Co. Inc., recently announced that it had hired Christopher S. James, M.D. as Managing Director, Equity Research covering biotechnology. Dr. James will be based in the firm’s New York Office.
Dr. Christopher S. James joins Ladenburg with more than a decade of experience as a biotechnology analyst focused on small, mid and large-cap companies across multiple therapeutic areas. Most recently, he worked for nearly 2 years as a Senior Biotechnology Equity Research Analyst at FBR Capital Markets. Prior to joining FBR, Dr. James held senior analyst roles at Brinson Patrick Securities, MLV & Co., and Rodman & Renshaw. Previously Dr. James served as Chief Medical Officer and SVP of Medical Affairs at Retrophin Inc., a public biotechnology company focused on developing orphan drug therapies to treat rare diseases.
Dr. James received his Medical Degree from the Yale University School of Medicine and a Bachelor of Science in Biology from Cornell University. He is a licensed physician with training in general surgery, neurology and neurosurgery from Weill-Cornell New York Hospital and Memorial Sloan Kettering Cancer Center.
David Rosenberg, Co-President and CEO of Ladenburg Thalmann said, “We are delighted to welcome Chris to Ladenburg. Chris has differentiated himself in the market with his experience covering a wide range of biotechnology companies and unique background as a physician, specifically as a neurosurgeon. We look forward to his insights and expertise as the newest member of our biotechnology team.”
Ladenburg Thalmann & Co. Inc., a division of publicly traded Ladenburg Thalmann Financial Services Inc, is a New York based investment bank which provides a full suite of investment banking and capital markets products and services, including proprietary equity research and a fixed-income trading desk.
Ladenburg Thalmann provides fundamental equity research coverage on approximately 170 stocks in the healthcare and life sciences; mortgage, equity & lodging REITs; energy, power & infrastructure; and telecom, media & technology sectors. With the addition of Dr. James, Ladenburg Thalman now employs 11 senior equity research analysts.
While Ladenburg Thalmann Financial Services has undertaken an aggressive acquisition plan starting in 2005, the investment bank has not added many new research analysts in recent years. In fact, the addition of Dr. James is actually a replacement for biotech analyst, Robert C. Hazlett, III who left the firm in the 4th Qtr of last year.